mitoxantrone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antineoplastics; anthraquinone derivatives | 1821 | 65271-80-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An anthracenedione-derived antineoplastic agent.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 7.50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 7 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.78 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 12 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 7.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.25 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 53 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 23, 1987 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 325.52 | 25.24 | 176 | 5684 | 105369 | 56180838 |
| Acute myeloid leukaemia | 246.61 | 25.24 | 85 | 5775 | 16887 | 56269320 |
| Myelodysplastic syndrome | 159.12 | 25.24 | 61 | 5799 | 16345 | 56269862 |
| Pancytopenia | 127.00 | 25.24 | 91 | 5769 | 88624 | 56197583 |
| Sepsis | 119.72 | 25.24 | 106 | 5754 | 139734 | 56146473 |
| Second primary malignancy | 118.88 | 25.24 | 40 | 5820 | 7362 | 56278845 |
| Acute promyelocytic leukaemia | 113.89 | 25.24 | 25 | 5835 | 909 | 56285298 |
| Neutropenia | 102.96 | 25.24 | 103 | 5757 | 158064 | 56128143 |
| Leukaemia recurrent | 84.66 | 25.24 | 21 | 5839 | 1307 | 56284900 |
| Thrombocytopenia | 83.64 | 25.24 | 86 | 5774 | 136138 | 56150069 |
| Acute myeloid leukaemia recurrent | 81.74 | 25.24 | 21 | 5839 | 1507 | 56284700 |
| Haemophagocytic lymphohistiocytosis | 73.21 | 25.24 | 30 | 5830 | 9542 | 56276665 |
| Bone marrow failure | 70.05 | 25.24 | 41 | 5819 | 28245 | 56257962 |
| Progressive multifocal leukoencephalopathy | 69.85 | 25.24 | 31 | 5829 | 11982 | 56274225 |
| Acute lymphocytic leukaemia recurrent | 64.40 | 25.24 | 19 | 5841 | 2278 | 56283929 |
| Bronchopulmonary aspergillosis | 63.54 | 25.24 | 26 | 5834 | 8238 | 56277969 |
| Febrile bone marrow aplasia | 58.57 | 25.24 | 23 | 5837 | 6549 | 56279658 |
| Chronic hepatitis | 56.81 | 25.24 | 14 | 5846 | 848 | 56285359 |
| Strongyloidiasis | 52.08 | 25.24 | 14 | 5846 | 1197 | 56285010 |
| Congestive cardiomyopathy | 50.58 | 25.24 | 20 | 5840 | 5799 | 56280408 |
| Lower respiratory tract infection fungal | 47.63 | 25.24 | 10 | 5850 | 293 | 56285914 |
| Cardiac failure | 47.02 | 25.24 | 50 | 5810 | 82043 | 56204164 |
| Chloroma | 44.67 | 25.24 | 9 | 5851 | 214 | 56285993 |
| Streptococcal bacteraemia | 44.60 | 25.24 | 13 | 5847 | 1494 | 56284713 |
| Mucormycosis | 44.56 | 25.24 | 15 | 5845 | 2759 | 56283448 |
| Haematotoxicity | 43.54 | 25.24 | 20 | 5840 | 8363 | 56277844 |
| Product use in unapproved indication | 42.26 | 25.24 | 62 | 5798 | 140760 | 56145447 |
| Abdominal wall wound | 40.24 | 25.24 | 7 | 5853 | 72 | 56286135 |
| Multiple organ dysfunction syndrome | 39.15 | 25.24 | 37 | 5823 | 52733 | 56233474 |
| Cardiomyopathy | 38.75 | 25.24 | 23 | 5837 | 16235 | 56269972 |
| Hypogammaglobulinaemia | 38.69 | 25.24 | 17 | 5843 | 6409 | 56279798 |
| Graft versus host disease | 37.81 | 25.24 | 17 | 5843 | 6764 | 56279443 |
| Venoocclusive liver disease | 37.74 | 25.24 | 15 | 5845 | 4406 | 56281801 |
| Bone marrow infiltration | 36.75 | 25.24 | 9 | 5851 | 531 | 56285676 |
| Myeloblast percentage decreased | 36.68 | 25.24 | 6 | 5854 | 41 | 56286166 |
| Refractory cytopenia with multilineage dysplasia | 35.85 | 25.24 | 7 | 5853 | 141 | 56286066 |
| Arthralgia | 35.69 | 25.24 | 5 | 5855 | 501664 | 55784543 |
| B precursor type acute leukaemia | 33.31 | 25.24 | 7 | 5853 | 206 | 56286001 |
| Aspergillus infection | 33.19 | 25.24 | 16 | 5844 | 7449 | 56278758 |
| Hepatitis E | 32.83 | 25.24 | 10 | 5850 | 1335 | 56284872 |
| Respiratory failure | 31.65 | 25.24 | 44 | 5816 | 95018 | 56191189 |
| Stem cell transplant | 30.28 | 25.24 | 10 | 5850 | 1734 | 56284473 |
| Stenotrophomonas infection | 30.07 | 25.24 | 10 | 5850 | 1771 | 56284436 |
| Pain | 29.89 | 25.24 | 16 | 5844 | 663168 | 55623039 |
| Bacterial sepsis | 29.51 | 25.24 | 12 | 5848 | 3737 | 56282470 |
| Clostridium bacteraemia | 28.22 | 25.24 | 6 | 5854 | 187 | 56286020 |
| Diffuse large B-cell lymphoma | 28.09 | 25.24 | 14 | 5846 | 7002 | 56279205 |
| Cardiotoxicity | 26.95 | 25.24 | 14 | 5846 | 7636 | 56278571 |
| Leukopenia | 26.91 | 25.24 | 35 | 5825 | 70905 | 56215302 |
| Neoplasm progression | 26.75 | 25.24 | 24 | 5836 | 31992 | 56254215 |
| Colitis | 26.67 | 25.24 | 27 | 5833 | 41784 | 56244423 |
| Differentiation syndrome | 26.47 | 25.24 | 8 | 5852 | 1041 | 56285166 |
| Streptococcal sepsis | 26.24 | 25.24 | 9 | 5851 | 1751 | 56284456 |
| Chronic myeloid leukaemia | 26.14 | 25.24 | 10 | 5850 | 2652 | 56283555 |
| Pyrexia | 26.06 | 25.24 | 99 | 5761 | 418674 | 55867533 |
| Pulmonary haemorrhage | 25.59 | 25.24 | 13 | 5847 | 6770 | 56279437 |
| Fatigue | 25.33 | 25.24 | 27 | 5833 | 788525 | 55497682 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 369.11 | 22.08 | 265 | 6823 | 121584 | 31568672 |
| Acute myeloid leukaemia | 203.47 | 22.08 | 94 | 6994 | 18578 | 31671678 |
| Myelodysplastic syndrome | 167.35 | 22.08 | 83 | 7005 | 19168 | 31671088 |
| Neutropenia | 110.75 | 22.08 | 146 | 6942 | 140218 | 31550038 |
| Septic shock | 108.33 | 22.08 | 101 | 6987 | 66057 | 31624199 |
| Mucormycosis | 83.08 | 22.08 | 35 | 7053 | 5535 | 31684721 |
| Bone marrow failure | 82.05 | 22.08 | 60 | 7028 | 27948 | 31662308 |
| Bronchopulmonary aspergillosis | 82.02 | 22.08 | 46 | 7042 | 13588 | 31676668 |
| Fungal infection | 71.36 | 22.08 | 43 | 7045 | 14508 | 31675748 |
| Acute lymphocytic leukaemia recurrent | 68.41 | 22.08 | 26 | 7062 | 3144 | 31687112 |
| Second primary malignancy | 63.06 | 22.08 | 31 | 7057 | 7001 | 31683255 |
| Leukaemia recurrent | 56.83 | 22.08 | 19 | 7069 | 1583 | 31688673 |
| Bacteraemia | 54.40 | 22.08 | 39 | 7049 | 17595 | 31672661 |
| Minimal residual disease | 53.05 | 22.08 | 13 | 7075 | 351 | 31689905 |
| Ameloblastoma | 50.67 | 22.08 | 10 | 7078 | 94 | 31690162 |
| Aspiration bone marrow abnormal | 49.67 | 22.08 | 10 | 7078 | 105 | 31690151 |
| Multiple organ dysfunction syndrome | 47.60 | 22.08 | 67 | 7021 | 68136 | 31622120 |
| Thrombocytopenia | 43.03 | 22.08 | 97 | 6991 | 142650 | 31547606 |
| Hypertensive hydrocephalus | 41.69 | 22.08 | 8 | 7080 | 64 | 31690192 |
| Pneumonia fungal | 39.81 | 22.08 | 22 | 7066 | 6307 | 31683949 |
| High-grade B-cell lymphoma | 39.69 | 22.08 | 9 | 7079 | 172 | 31690084 |
| Venoocclusive liver disease | 39.19 | 22.08 | 23 | 7065 | 7389 | 31682867 |
| Haematopoietic neoplasm | 37.30 | 22.08 | 7 | 7081 | 49 | 31690207 |
| Neoplasm progression | 37.10 | 22.08 | 33 | 7055 | 20239 | 31670017 |
| Myelosuppression | 37.09 | 22.08 | 29 | 7059 | 14891 | 31675365 |
| Cardiotoxicity | 35.87 | 22.08 | 19 | 7069 | 5008 | 31685248 |
| Mucosal inflammation | 35.35 | 22.08 | 41 | 7047 | 34386 | 31655870 |
| Abscess fungal | 34.74 | 22.08 | 8 | 7080 | 164 | 31690092 |
| Aspergillus infection | 34.41 | 22.08 | 25 | 7063 | 11503 | 31678753 |
| Cytogenetic abnormality | 34.18 | 22.08 | 11 | 7077 | 813 | 31689443 |
| Neoplasm recurrence | 33.92 | 22.08 | 14 | 7074 | 2100 | 31688156 |
| Disease progression | 33.62 | 22.08 | 67 | 7021 | 90397 | 31599859 |
| Clostridium bacteraemia | 33.11 | 22.08 | 7 | 7081 | 95 | 31690161 |
| Cystitis haemorrhagic | 32.21 | 22.08 | 18 | 7070 | 5271 | 31684985 |
| Pancytopenia | 31.65 | 22.08 | 64 | 7024 | 87252 | 31603004 |
| Sepsis | 30.90 | 22.08 | 89 | 6999 | 151840 | 31538416 |
| Klebsiella infection | 30.55 | 22.08 | 20 | 7068 | 7783 | 31682473 |
| Febrile bone marrow aplasia | 30.45 | 22.08 | 20 | 7068 | 7826 | 31682430 |
| Gallbladder adenocarcinoma | 30.10 | 22.08 | 5 | 7083 | 15 | 31690241 |
| Refractory anaemia with an excess of blasts | 27.56 | 22.08 | 8 | 7080 | 417 | 31689839 |
| Neutropenic colitis | 27.56 | 22.08 | 13 | 7075 | 2679 | 31687577 |
| Respiratory tract infection fungal | 27.43 | 22.08 | 9 | 7079 | 707 | 31689549 |
| Product use in unapproved indication | 27.21 | 22.08 | 65 | 7023 | 99106 | 31591150 |
| Acute lymphocytic leukaemia | 27.15 | 22.08 | 14 | 7074 | 3492 | 31686764 |
| Genotoxicity | 26.52 | 22.08 | 5 | 7083 | 36 | 31690220 |
| Enamel anomaly | 26.25 | 22.08 | 6 | 7082 | 119 | 31690137 |
| Encephalopathy | 25.80 | 22.08 | 34 | 7054 | 32440 | 31657816 |
| Klebsiella sepsis | 25.48 | 22.08 | 11 | 7077 | 1844 | 31688412 |
| Progressive multifocal leukoencephalopathy | 25.29 | 22.08 | 19 | 7069 | 9194 | 31681062 |
| Acute myeloid leukaemia recurrent | 24.82 | 22.08 | 11 | 7077 | 1963 | 31688293 |
| Osteonecrosis | 24.21 | 22.08 | 22 | 7066 | 13862 | 31676394 |
| Hyperammonaemic encephalopathy | 23.56 | 22.08 | 11 | 7077 | 2215 | 31688041 |
| Colitis | 23.18 | 22.08 | 33 | 7055 | 33854 | 31656402 |
| Large granular lymphocytosis | 23.04 | 22.08 | 6 | 7082 | 208 | 31690048 |
| Fungaemia | 22.90 | 22.08 | 11 | 7077 | 2358 | 31687898 |
| Differentiation syndrome | 22.64 | 22.08 | 9 | 7079 | 1226 | 31689030 |
| Drug resistance | 22.52 | 22.08 | 27 | 7061 | 23426 | 31666830 |
| Cholangitis infective | 22.33 | 22.08 | 6 | 7082 | 235 | 31690021 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 564.47 | 20.79 | 370 | 11014 | 203948 | 70713112 |
| Acute myeloid leukaemia | 429.73 | 20.79 | 168 | 11216 | 30772 | 70886288 |
| Myelodysplastic syndrome | 318.18 | 20.79 | 134 | 11250 | 29651 | 70887409 |
| Neutropenia | 184.12 | 20.79 | 216 | 11168 | 256940 | 70660120 |
| Second primary malignancy | 174.43 | 20.79 | 69 | 11315 | 12982 | 70904078 |
| Bone marrow failure | 149.88 | 20.79 | 95 | 11289 | 48915 | 70868145 |
| Leukaemia recurrent | 122.63 | 20.79 | 36 | 11348 | 2739 | 70914321 |
| Sepsis | 119.20 | 20.79 | 170 | 11214 | 244375 | 70672685 |
| Acute lymphocytic leukaemia recurrent | 117.99 | 20.79 | 40 | 11344 | 4864 | 70912196 |
| Septic shock | 112.89 | 20.79 | 113 | 11271 | 112145 | 70804915 |
| Thrombocytopenia | 108.91 | 20.79 | 161 | 11223 | 238949 | 70678111 |
| Bronchopulmonary aspergillosis | 102.06 | 20.79 | 55 | 11329 | 20947 | 70896113 |
| Acute promyelocytic leukaemia | 100.67 | 20.79 | 27 | 11357 | 1475 | 70915585 |
| Pancytopenia | 96.53 | 20.79 | 120 | 11264 | 150987 | 70766073 |
| Mucormycosis | 95.41 | 20.79 | 39 | 11345 | 7975 | 70909085 |
| Acute myeloid leukaemia recurrent | 85.79 | 20.79 | 28 | 11356 | 3026 | 70914034 |
| Venoocclusive liver disease | 81.53 | 20.79 | 38 | 11346 | 10640 | 70906420 |
| Multiple organ dysfunction syndrome | 77.12 | 20.79 | 91 | 11293 | 108424 | 70808636 |
| Progressive multifocal leukoencephalopathy | 76.11 | 20.79 | 44 | 11340 | 19170 | 70897890 |
| Bacteraemia | 70.62 | 20.79 | 49 | 11335 | 29260 | 70887800 |
| Fungal infection | 68.45 | 20.79 | 53 | 11331 | 37414 | 70879646 |
| Product use in unapproved indication | 62.37 | 20.79 | 116 | 11268 | 207362 | 70709698 |
| Febrile bone marrow aplasia | 59.92 | 20.79 | 32 | 11352 | 11959 | 70905101 |
| Clostridium bacteraemia | 59.45 | 20.79 | 13 | 11371 | 296 | 70916764 |
| Ameloblastoma | 53.98 | 20.79 | 10 | 11374 | 94 | 70916966 |
| Neoplasm recurrence | 53.20 | 20.79 | 21 | 11363 | 3920 | 70913140 |
| Aspergillus infection | 52.99 | 20.79 | 34 | 11350 | 17834 | 70899226 |
| Haemophagocytic lymphohistiocytosis | 52.50 | 20.79 | 35 | 11349 | 19577 | 70897483 |
| Cytogenetic abnormality | 52.37 | 20.79 | 15 | 11369 | 1045 | 70916015 |
| Lower respiratory tract infection fungal | 50.53 | 20.79 | 14 | 11370 | 864 | 70916196 |
| Refractory anaemia with an excess of blasts | 50.22 | 20.79 | 14 | 11370 | 884 | 70916176 |
| Chronic hepatitis | 49.28 | 20.79 | 15 | 11369 | 1291 | 70915769 |
| Acute lymphocytic leukaemia | 46.29 | 20.79 | 21 | 11363 | 5524 | 70911536 |
| Neoplasm progression | 46.26 | 20.79 | 46 | 11338 | 45182 | 70871878 |
| Respiratory failure | 45.34 | 20.79 | 90 | 11294 | 168645 | 70748415 |
| Cardiomyopathy | 45.34 | 20.79 | 36 | 11348 | 26337 | 70890723 |
| Differentiation syndrome | 45.05 | 20.79 | 16 | 11368 | 2231 | 70914829 |
| Drug resistance | 45.02 | 20.79 | 42 | 11342 | 38148 | 70878912 |
| Cardiotoxicity | 42.90 | 20.79 | 25 | 11359 | 11045 | 70906015 |
| Fungaemia | 42.31 | 20.79 | 18 | 11366 | 4064 | 70912996 |
| Klebsiella sepsis | 41.45 | 20.79 | 16 | 11368 | 2815 | 70914245 |
| High-grade B-cell lymphoma | 40.75 | 20.79 | 9 | 11375 | 215 | 70916845 |
| Staphylococcal infection | 39.92 | 20.79 | 46 | 11338 | 53358 | 70863702 |
| Myelosuppression | 39.14 | 20.79 | 35 | 11349 | 30110 | 70886950 |
| Fatigue | 39.11 | 20.79 | 45 | 11339 | 824274 | 70092786 |
| Enterococcal infection | 38.97 | 20.79 | 26 | 11358 | 14556 | 70902504 |
| Stenotrophomonas infection | 38.84 | 20.79 | 16 | 11368 | 3333 | 70913727 |
| Aplastic anaemia | 38.05 | 20.79 | 27 | 11357 | 16689 | 70900371 |
| Haematotoxicity | 38.04 | 20.79 | 25 | 11359 | 13649 | 70903411 |
| Stem cell transplant | 37.79 | 20.79 | 16 | 11368 | 3569 | 70913491 |
| Arthralgia | 37.48 | 20.79 | 17 | 11367 | 503373 | 70413687 |
| Disease progression | 36.71 | 20.79 | 79 | 11305 | 156593 | 70760467 |
| Colitis | 36.45 | 20.79 | 48 | 11336 | 63766 | 70853294 |
| Malignant neoplasm progression | 36.45 | 20.79 | 68 | 11316 | 121671 | 70795389 |
| Abdominal wall wound | 36.30 | 20.79 | 7 | 11377 | 83 | 70916977 |
| Haematopoietic neoplasm | 36.00 | 20.79 | 7 | 11377 | 87 | 70916973 |
| Cardiac failure | 35.50 | 20.79 | 74 | 11310 | 143467 | 70773593 |
| Neutropenic colitis | 35.35 | 20.79 | 17 | 11367 | 5097 | 70911963 |
| Cystitis haemorrhagic | 34.88 | 20.79 | 20 | 11364 | 8573 | 70908487 |
| Pain | 34.75 | 20.79 | 30 | 11354 | 628786 | 70288274 |
| Pneumonia fungal | 34.71 | 20.79 | 21 | 11363 | 9932 | 70907128 |
| Klebsiella infection | 34.66 | 20.79 | 24 | 11360 | 14268 | 70902792 |
| Hyperammonaemic encephalopathy | 34.50 | 20.79 | 16 | 11368 | 4427 | 70912633 |
| Hypogammaglobulinaemia | 34.32 | 20.79 | 22 | 11362 | 11516 | 70905544 |
| Respiratory tract infection fungal | 34.13 | 20.79 | 11 | 11373 | 1142 | 70915918 |
| Myeloblast percentage decreased | 34.08 | 20.79 | 6 | 11378 | 41 | 70917019 |
| Chloroma | 34.08 | 20.79 | 10 | 11374 | 759 | 70916301 |
| Refractory cytopenia with multilineage dysplasia | 33.73 | 20.79 | 8 | 11376 | 264 | 70916796 |
| Graft versus host disease | 33.58 | 20.79 | 24 | 11360 | 14999 | 70902061 |
| Candida infection | 33.30 | 20.79 | 34 | 11350 | 34439 | 70882621 |
| Hypertensive hydrocephalus | 33.20 | 20.79 | 5 | 11379 | 10 | 70917050 |
| Stomatococcal infection | 33.20 | 20.79 | 8 | 11376 | 283 | 70916777 |
| Bone marrow infiltration | 32.94 | 20.79 | 9 | 11375 | 527 | 70916533 |
| Chronic lymphocytic leukaemia recurrent | 31.72 | 20.79 | 9 | 11375 | 606 | 70916454 |
| Diffuse large B-cell lymphoma recurrent | 31.68 | 20.79 | 14 | 11370 | 3462 | 70913598 |
| Hepatic failure | 30.85 | 20.79 | 42 | 11342 | 57583 | 70859477 |
| Pyrexia | 30.76 | 20.79 | 184 | 11200 | 606768 | 70310292 |
| Strongyloidiasis | 30.76 | 20.79 | 14 | 11370 | 3709 | 70913351 |
| Pruritus | 30.19 | 20.79 | 9 | 11375 | 345551 | 70571509 |
| Fall | 30.04 | 20.79 | 17 | 11367 | 444079 | 70472981 |
| Mucosal inflammation | 29.79 | 20.79 | 45 | 11339 | 67805 | 70849255 |
| Chronic myeloid leukaemia | 29.15 | 20.79 | 14 | 11370 | 4187 | 70912873 |
| Drug hypersensitivity | 28.77 | 20.79 | 4 | 11380 | 262455 | 70654605 |
| Abscess fungal | 28.77 | 20.79 | 7 | 11377 | 258 | 70916802 |
| Encephalopathy | 28.65 | 20.79 | 42 | 11342 | 61619 | 70855441 |
| Pulmonary haemorrhage | 28.64 | 20.79 | 21 | 11363 | 13652 | 70903408 |
| Osteonecrosis | 28.60 | 20.79 | 29 | 11355 | 29131 | 70887929 |
| Nausea | 28.43 | 20.79 | 59 | 11325 | 852029 | 70065031 |
| Acute febrile neutrophilic dermatosis | 28.34 | 20.79 | 13 | 11371 | 3506 | 70913554 |
| Hepatitis B | 27.99 | 20.79 | 17 | 11367 | 8097 | 70908963 |
| Aspiration bone marrow abnormal | 27.26 | 20.79 | 6 | 11378 | 141 | 70916919 |
| Disseminated intravascular coagulation | 26.91 | 20.79 | 30 | 11354 | 33568 | 70883492 |
| Pseudomonas infection | 26.55 | 20.79 | 23 | 11361 | 18971 | 70898089 |
| Streptococcal bacteraemia | 26.50 | 20.79 | 12 | 11372 | 3141 | 70913919 |
| Lymphopenia | 26.45 | 20.79 | 27 | 11357 | 27332 | 70889728 |
| Leukopenia | 26.41 | 20.79 | 55 | 11329 | 106505 | 70810555 |
| Pain in extremity | 26.13 | 20.79 | 10 | 11374 | 328072 | 70588988 |
| Blood culture positive | 25.79 | 20.79 | 16 | 11368 | 7910 | 70909150 |
| Dizziness | 25.78 | 20.79 | 22 | 11362 | 464119 | 70452941 |
| Minimal residual disease | 25.57 | 20.79 | 7 | 11377 | 413 | 70916647 |
| Nasopharyngitis | 25.28 | 20.79 | 3 | 11381 | 222203 | 70694857 |
| Hepatitis E | 25.06 | 20.79 | 11 | 11373 | 2677 | 70914383 |
| Escherichia bacteraemia | 24.73 | 20.79 | 14 | 11370 | 5855 | 70911205 |
| Chromosome analysis abnormal | 24.58 | 20.79 | 6 | 11378 | 224 | 70916836 |
| Portal hypertension | 23.42 | 20.79 | 14 | 11370 | 6478 | 70910582 |
| Cytomegalovirus infection | 22.84 | 20.79 | 30 | 11354 | 39728 | 70877332 |
| Acute myelomonocytic leukaemia | 22.81 | 20.79 | 6 | 11378 | 304 | 70916756 |
| Pseudomonal sepsis | 22.77 | 20.79 | 13 | 11371 | 5524 | 70911536 |
| Streptococcal sepsis | 22.74 | 20.79 | 10 | 11374 | 2444 | 70914616 |
| Graft versus host disease in gastrointestinal tract | 21.92 | 20.79 | 13 | 11371 | 5931 | 70911129 |
| Cerebral fungal infection | 21.88 | 20.79 | 6 | 11378 | 356 | 70916704 |
| Leukaemic infiltration | 21.84 | 20.79 | 5 | 11379 | 141 | 70916919 |
| Large granular lymphocytosis | 21.79 | 20.79 | 6 | 11378 | 362 | 70916698 |
| Weight increased | 21.73 | 20.79 | 6 | 11378 | 242325 | 70674735 |
| Metastasis | 21.58 | 20.79 | 13 | 11371 | 6101 | 70910959 |
| Bacterial sepsis | 21.31 | 20.79 | 14 | 11370 | 7633 | 70909427 |
| Primary hypogonadism | 20.88 | 20.79 | 5 | 11379 | 172 | 70916888 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01DB07 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances |
| FDA MoA | N0000000176 | Topoisomerase Inhibitors |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D059005 | Topoisomerase II Inhibitors |
| FDA EPC | N0000175609 | Topoisomerase Inhibitor |
| CHEBI has role | CHEBI:23240 | chromophores |
| CHEBI has role | CHEBI:37958 | dyes |
| CHEBI has role | CHEBI:76924 | plant metabolites |
| CHEBI has role | CHEBI:35610 | antineoplastic agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute myeloid leukemia, disease | indication | 91861009 | |
| Relapsing remitting multiple sclerosis | indication | 426373005 | DOID:2378 |
| Metastatic Prostate Carcinoma | indication | ||
| Follicular non-Hodgkin's lymphoma | off-label use | 308121000 | |
| Metastatic Breast Carcinoma | off-label use | ||
| Progressive Diffuse Large B-Cell Lymphoma | off-label use | ||
| Mycosis | contraindication | 3218000 | DOID:1564 |
| Viral disease | contraindication | 34014006 | DOID:934 |
| Chronic heart failure | contraindication | 48447003 | |
| Hepatic failure | contraindication | 59927004 | |
| Acute infectious disease | contraindication | 63171007 | |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Left heart failure | contraindication | 85232009 | |
| Bacterial infectious disease | contraindication | 87628006 | |
| Radiation oncology AND/OR radiotherapy | contraindication | 108290001 | |
| Acute disease of cardiovascular system | contraindication | 128487001 | |
| Seizure disorder | contraindication | 128613002 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Bone marrow depression | contraindication | 307762000 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.37 | acidic |
| pKa2 | 10.7 | acidic |
| pKa3 | 9.13 | Basic |
| pKa4 | 8.52 | Basic |
| pKa5 | 4.01 | Basic |
| pKa6 | 1.49 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| DNA topoisomerase 2-alpha | Enzyme | INHIBITOR | IC90 | 5.96 | WOMBAT-PK | CHEMBL | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | Ki | 5.53 | DRUG MATRIX | |||||
| Multidrug resistance protein 1 | Transporter | IC50 | 5.84 | WOMBAT-PK | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.31 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.73 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.74 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.11 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.05 | DRUG MATRIX | |||||
| Canalicular multispecific organic anion transporter 1 | Transporter | WOMBAT-PK | |||||||
| Multidrug resistance-associated protein 1 | Transporter | IC50 | 6.29 | WOMBAT-PK | |||||
| ATP-binding cassette sub-family G member 2 | Transporter | Kact | 5.16 | WOMBAT-PK | |||||
| Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.90 | DRUG MATRIX | |||||
| Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 5.69 | DRUG MATRIX | |||||
| Serine/threonine-protein kinase pim-1 | Kinase | IC50 | 7.29 | CHEMBL | |||||
| Solute carrier family 22 member 1 | Transporter | IC50 | 4.36 | CHEMBL | |||||
| DNA-(apurinic or apyrimidinic site) lyase | Enzyme | IC50 | 5.70 | CHEMBL | |||||
| Tyrosine-protein kinase BTK | Kinase | IC50 | 6 | CHEMBL | |||||
| Proto-oncogene tyrosine-protein kinase ROS | Kinase | IC50 | 5.52 | CHEMBL | |||||
| Solute carrier family 22 member 2 | Transporter | IC50 | 4.13 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 6.72 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 6.28 | CHEMBL | |||||
| Solute carrier family 22 member 3 | Transporter | IC50 | 4.22 | CHEMBL | |||||
| DNA-3-methyladenine glycosylase | Enzyme | IC50 | 5.60 | CHEMBL | |||||
| Epidermal growth factor receptor | Kinase | IC50 | 5.27 | DRUG MATRIX | |||||
| TAR DNA-binding protein 43 | Unclassified | IC50 | 5 | CHEMBL | |||||
| Arachidonate 15-lipoxygenase | Enzyme | IC50 | 5.75 | DRUG MATRIX | |||||
| Integrase | Enzyme | IC50 | 5.42 | CHEMBL | |||||
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Kinase | AC50 | 5.02 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019842 | VUID |
| N0000147929 | NUI |
| D02166 | KEGG_DRUG |
| 70476-82-3 | SECONDARY_CAS_RN |
| 4019527 | VANDF |
| 4019842 | VANDF |
| C0026259 | UMLSCUI |
| CHEBI:50729 | CHEBI |
| MIX | PDB_CHEM_ID |
| CHEMBL58 | ChEMBL_ID |
| CHEMBL1417019 | ChEMBL_ID |
| CHEMBL1200827 | ChEMBL_ID |
| D008942 | MESH_DESCRIPTOR_UI |
| DB01204 | DRUGBANK_ID |
| 7242 | IUPHAR_LIGAND_ID |
| 4922 | INN_ID |
| BZ114NVM5P | UNII |
| 4212 | PUBCHEM_CID |
| 203129 | RXNORM |
| 5124 | MMSL |
| 81184 | MMSL |
| d00306 | MMSL |
| 002676 | NDDF |
| 004828 | NDDF |
| 108791001 | SNOMEDCT_US |
| 386913001 | SNOMEDCT_US |
| 412249002 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| mitoXANTRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4680 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 24 sections |
| mitoXANTRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4680 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 24 sections |
| mitoXANTRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4685 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 24 sections |
| mitoXANTRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4685 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 24 sections |
| mitoXANTRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4686 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 24 sections |
| mitoXANTRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-4686 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 24 sections |
| Mitoxantrone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61703-343 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 28 sections |
| Mitoxantrone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61703-343 | INJECTION, SOLUTION, CONCENTRATE | 2 mg | INTRAVENOUS | ANDA | 28 sections |
| Mitoxantrone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-132 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | ANDA | 15 sections |